No Preemption Split To Resolve In Reglan Case, Justices Told
The consumers who alleged that Pliva Inc. and other drugmakers didn't adequately warn about the neurological risks of generic Reglan have urged the U.S. Supreme Court to reject the companies' petition...To view the full article, register now.
Already a subscriber? Click here to view full article